Prestige Consumer Healthcare Inc. (NYSE:PBH) Insider Sells $735,585.95 in Stock

Prestige Consumer Healthcare Inc. (NYSE:PBH) insider William P’pool sold 8,987 shares of the company’s stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $81.85, for a total transaction of $735,585.95. Following the sale, the insider now directly owns 20,058 shares in the company, valued at $1,641,747.30. This trade represents a 30.94 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Prestige Consumer Healthcare Trading Up 0.6 %

Prestige Consumer Healthcare stock traded up $0.49 during trading hours on Thursday, reaching $82.81. The stock had a trading volume of 337,716 shares, compared to its average volume of 250,663. The company has a fifty day simple moving average of $72.98 and a 200-day simple moving average of $70.09. The stock has a market cap of $4.09 billion, a PE ratio of 20.05, a PEG ratio of 2.30 and a beta of 0.47. The company has a debt-to-equity ratio of 0.61, a current ratio of 3.56 and a quick ratio of 2.10. Prestige Consumer Healthcare Inc. has a 52 week low of $56.61 and a 52 week high of $83.83.

Prestige Consumer Healthcare (NYSE:PBH) last announced its earnings results on Thursday, November 7th. The company reported $1.09 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.09. The firm had revenue of $283.79 million for the quarter, compared to analyst estimates of $282.09 million. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The company’s revenue for the quarter was down .9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.07 EPS. Analysts forecast that Prestige Consumer Healthcare Inc. will post 4.45 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have commented on PBH shares. Jefferies Financial Group reiterated a “hold” rating and issued a $76.00 price objective (up previously from $70.00) on shares of Prestige Consumer Healthcare in a research note on Tuesday, September 24th. DA Davidson restated a “buy” rating and set a $95.00 price objective on shares of Prestige Consumer Healthcare in a research report on Monday. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $94.20.

Institutional Investors Weigh In On Prestige Consumer Healthcare

Several hedge funds have recently bought and sold shares of the business. Martingale Asset Management L P boosted its stake in Prestige Consumer Healthcare by 0.4% during the third quarter. Martingale Asset Management L P now owns 36,971 shares of the company’s stock worth $2,666,000 after acquiring an additional 140 shares in the last quarter. Covestor Ltd raised its holdings in Prestige Consumer Healthcare by 21.6% in the first quarter. Covestor Ltd now owns 834 shares of the company’s stock worth $61,000 after buying an additional 148 shares during the last quarter. Horizon Kinetics Asset Management LLC raised its holdings in Prestige Consumer Healthcare by 4.8% in the third quarter. Horizon Kinetics Asset Management LLC now owns 3,247 shares of the company’s stock worth $234,000 after buying an additional 150 shares during the last quarter. Evergreen Capital Management LLC raised its holdings in shares of Prestige Consumer Healthcare by 5.4% during the second quarter. Evergreen Capital Management LLC now owns 3,143 shares of the company’s stock valued at $216,000 after purchasing an additional 160 shares during the last quarter. Finally, Miller Howard Investments Inc. NY raised its holdings in shares of Prestige Consumer Healthcare by 2.2% during the second quarter. Miller Howard Investments Inc. NY now owns 7,762 shares of the company’s stock valued at $534,000 after purchasing an additional 165 shares during the last quarter. Institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.